Multidisciplinary health care monitoring and training program: impact on antibiotic use

Abstract

Aim. To develop a program for monitoring the use of antibacterial agents and training in their rational use using the information on consumption and expenses in a multidisciplinary healthcare institution.

Methods. From 2011 to 2014, a group of clinical pharmacologists developed and implemented a monitoring program for the use of antibacterial agents using the ATC/DDD and ABC/VEN methodology in SBIH “Penza Regional Clinical Hospital named after N.N. Burdenko”. Hospital doctors were trained in the principles of rational use of drugs and antibiotics as part of continuing education in clinical pharmacology using monitoring results — analysis of the costs and consumption of antibacterial agents.

Results. Over the four years of monitoring and three years of educational activities, the most pronounced changes have occurred in the use of fluoroquinolones, aminoglycosides, macrolides and carbapenems. Fluoroquinolones consumption reduced 2 times, and it cost of purchase reduced 6 times (of total). Aminoglycosides consumption increased 3 times, primarily due to amikacin 5 times consumption increase. Macrolides consumption reduced 3 times, primarily due to clarithromycin decrease in consumption. At the same time, the antibacterial agents of the cephalosporin group leading in consumption, with their cost had decreased 2-fold. However, carbapenems consumption increased 3 times, with their costs increase 7 times.

Conclusion. Over the three years of the program, expenses and consumption of antibacterial agents of the fluoroquinolone and macrolide group were reduced, with an increase in the consumption of aminoglycosides and carbapenems without changes in the consumption of cephalosporins; costs of cephalosporins and carbapenems led to an increase in overall antibiotic costs; further efforts and studies are needed to study the use of antibacterial agents.

Keywords

pharmacoepidemiology / drug use / antibiotics

References

[1] Belkova Y.A., Rachina S.A., Koz­lov R.S. et al. Systemic antimicrobials consumption and expenditures in multi-profile hospitals in Russian Federation and Republic of Belarus: the results of multicenter pharmacoepidemiological trial. Klinicheskaya mikrobiolo­giya i antimikrobnaya khimioterapiya. 2012; 14 (4): 322–341. (In Russ.)

[2] Белькова Ю.А., Рачина С.А., Козлов Р.С. и др. Потребление и затраты на системные антимикробные препараты в многопрофильных стационарах Российской Федерации и Республики Беларусь: результаты многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. и антимикроб. химиотерап. 2012; 14 (4): 322–341.

[3] Friedrich M.J. Antibiotic consumption increa­sing globally. JAMA. 2018; 319 (19): 1973. DOI: 10.1001/jama.2018.5711.

[4] Sukhorukova M.V., Edelshtein M.V., Skleenova E.Yu. et al. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of national multicenter surveillance study MARATHON 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimiote­rapiya. 2014; 16 (4): 254–265. (In Russ.)

[5] Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Enterobacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин. микробиол. и антимикроб. химиотерап. 2014; 16 (4): 254–265.

[6] Sukhorukova M.V., Edelshtein M.V., Skle­enova E.Yu. et al. Antimicrobial resistance of nosocomial Staphylococcus aureus isolates in Russia: results of natio­nal multicenter surveillance study MARATHON 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014; 16 (4): 280–286. (In Russ.)

[7] Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus aureus в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин. микробиол. и антимикроб. химиотерап. 2014; 16 (4): 280–286.

[8] Sukhorukova M.V., Edelshtein M.V., Skle­enova E.Yu. et al. Antimicrobial resistance of nosoco­mial Acinetobacter spp. isolates in Russia: results of national multicenter surveillance study MARATHON 2011–2012. Klinicheskaya mikrobiologiya i antimikrobnaya khimiote­rapiya. 2014; 16 (4): 266–272. (In Russ.)

[9] Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и др. Антибиотикорезистентность нозокомиальных штаммов Acinetobacter spp. в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин. микробиол. и aнтимикроб. химиотерап. 2014; 16 (4): 266–272.

[10] Gastmeier P., Behnke M., Breier A.C. et al. Healthcare-associated infection rates: measuring and comparing. Experiences from the German National Nosocomial Infection Surveillance System (KISS) and from other survei­llance systems. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012; 55 (11–12): 1363–1369. DOI: 10.1007/s00103-012-1551-y.

[11] Yakovlev S.V., Suvorova N.P., Beloborodov V.V. et al. Multicentre study of the prevalence and clinical value of hospital-acquired infections in emergency hospitals of Russia: ERGINI study team. Antibiotiki i khimioterapiya. 2016; 61 (5–6): 32–42. (In Russ.)

[12] Яковлев С.В., Суворова Н.П., Белобородов В.В. и др. Распространённость и клиническое значение нозокомиальных инфекций в лечебных учреждениях России: исследование ЭРГИНИ. Антибиотики и химиотерапия. 2016; 61 (5–6): 32–42.

[13] Kraker M.E., Davey P.G., Grundmann H. Morta­lity and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estima­ting the burden of antibiotic resistance in Europe. PLoS Medicine. 2011; 8 (10): 1001–1104. DOI: 10.1371/journal.pmed.1001104.

[14] Carlet J., Fabry J., Amalberti R., Degos L. The “Zero Risk” Concept for hospital-acquired infections: A risky business! Clin. Infect. Dis. 2009; 49 (5): 747–749. DOI: 10.1086/604720.

[15] Belkova Y.A., Rachina S.A., Kozlov R.S. et al. Antimicro­bial stewardship: international practices and implementation prospects in the Russian hospitals. Klinicheskaya farmakologiya i terapiya. 2019; 28 (4): 4–9. (In Russ.) DOI: 10.32756/0869-5490-2019-4-4-9.

[16] Белькова Ю.А., Рачина С.А., Козлов Р.С. и др. Управление антимикробной терапией: зарубежный опыт и перспективы внедрения в российских стационарах. Клин. фармакол. терап. 2019; 28 (4): 4–9. DOI: 10.32756/0869-5490-2019-4-4-9.

[17] Dellit T.H., Owens R.C., McGowan J.E. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicro­bial stewardship. Clin. Infect. Dis. 2007; 44: 159–177. DOI: 10.1086/510393.

[18] Arnold S., Straus S. Interventions to improve antibiotic prescribing practices in ambulatory care. Coch­rane Database of Systematic Reviews. 2005; 2005 (4): CD003539. DOI: 10.1002/14651858.CD003539.pub2.

[19] Davey P., Marwick C.A., Scott C.L. et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews. 2017; 2 (2): CD003543. DOI: 10.1002/14651858.CD003543.pub4.

[20] Programma SKAT (Strategiya Kontrolya Antimikrobnoy Terapii) pri okazanii statsio­narnoy meditsinskoy pomoshchi. Rossiyskie klini­cheskie rekomendatsii. (SCAT (Antimicrobial Therapy Control Strategy) program for inpatient care. Russian clinical guidelines.) M. 2017; 132 р. (In Russ.)

[21] Программа СКАТ (Стратегия Контроля Антимикробной Терапии) при оказании стационарной медицинской помощи. Российские клинические рекомендации. М. 2017; 132 с.

[22] Rachina S.A., Zakharenkov I.A., Belkova Yu.A. et al. Point prevalence survey of antimicrobial utilization in Russian multi-field hospitals. Klinicheskaya farmakologiya i terapiya. 2017; 26 (2): 62–69. (In Russ.)

[23] Рачина С.А., Захаренков И.А., Белькова Ю.А. и др. Одномоментное исследование использования антимикробных препаратов в многопрофильных стационарах Российской Федерации. Клин. фармакол. терап. 2017; 26 (2): 62–69.

[24] Ziganshina L.E., Magsumova D.R., Kuchaeva A.V. et al. ATS/DDD — klassifikatsionnaya sistema v farmakoepidemiologicheskikh issledovaniyakh. Kachestvennaya klinicheskaya praktika. 2004; (1): 28–33. (In Russ.)

[25] Зиганшина Л.Е., Магсумова Д.Р., Кучаева А.В. и др. АТС/DDD — классификационная система в фармакоэпидемиологических исследованиях. Качественная клин. практика. 2004; (1): 28–33.

[26] WHO Collaborating Centre for Drug Statistics Methodology. htpp://www.whocc.no/atc_ddd_index/ (access date: 10.02.2015).

[27] Yevstigneev S.V., Alexandrova E.G., Abakumova T.R. et al. Consumption of antimicrobials at a multi-disciplinary hospital: ATC/DDD metho­dology. Zhurnal nauchnykh statey zdorov'e i obrazovanie v XXI veke. 2017; 19 (7): 131–137. (In Russ.)

[28] Евстигнеев С.В., Александрова Э.Г., Абакумова Т.Р. и др. Оценка потребления антибактериальных лекарственных средств в многопрофильном стационаре, проведённая по методологии ATC/DDD анализа. Ж. научных статей здоровье и образование в XXI веке. 2017; 19 (7): 131–137.

[29] Yevstigneev S.V., Titarenko A.F., Abakumova T.R. et al. Towards the rational use of medicines. Int. J. Risk Saf. Med. 2015; 27 (1): 59–60. DOI: 10.3233/JRS-150690.

[30] Krasnozhon T.V., Dyachenko S.V., Adaev A.M., Bondarenko O.A. Pharmacoepidemiological analysis of antimicrobial drugs in a multidisciplinary surgical hospital. Dal'nevostochnyy meditsinskiy zhurnal. 2013; (3): 118–121. (In Russ.)

[31] Красножон Т.В., Дьяченко С.В., Адаев А.М., Бондаренко О.А. Фармакоэпидемиологический анализ использования антимикробных препаратов в многопрофильном хирургическом стационаре. Дальневосточный мед. ж. 2013; (3): 118–121.

[32] Barkanova O.N., Rebrova E.V., Ilchenko O.V. et al. Analysis of antibiotic consumption in surgical departments of Volgograd hospitals in 2014. Vestnik VolGMU. 2015; (3): 93–96. (In Russ.)

[33] Барканова О.Н., Реброва Е.В., Ильченко О.В. и др. Анализ потребления антибактериальных препаратов в хирургических отделениях стационаров г. Волгограда в 2014 г. Вестн. ВолГМУ. 2015; (3): 93–96.

[34] Loeb M., Salama S., Armstrong-Evans M. et al. A case-control study to detect modifiable risk factors for co­lonization with vancomycin-resistant enterococci. ­Infect. Control Hosp. Epidemiol. 1999; 20: 760–763. DOI: 10.1086/501580.

[35] Messadi A.A., Lamia T., Kamel B., Capretta G. Association between antibiotic use and changes in susceptibility patterns of P. aeruginosa in an intensive care unit: a 5-year study, 2000–2004. Burns. 2008; 34: 1098–1102. DOI: 10.1016/j.burns.2008.03.014.

[36] Sarma J.B., Ahmed G.U. Characterisation of me­thicillin resistant S. aureus strains and risk factors for acquisition in a teaching hospital in northeast India. Indian J. Med. Microbiol. 2010; 28: 127–129. DOI: 10.4103/0255-0857.62489.

[37] Belkova Y.A., Rachina S.A., Kozlov R.S. et al. Systemic antimicrobials consumption and expenditures in intensive care units of hospitals in Russian Federation and Republic of Belarus: results of multicenter pharmacoepidemiological study. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2014; 16 (4): 294–311. (In Russ.)

[38] Белькова Ю.А., Рачина С.А., Козлов Р.С. и др. Потребление и затраты на системные антимикробные препараты в отделениях реанимации и интенсивной терапии многопрофильных стационаров Российской Федерации и Республики Беларусь: результаты многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. антимикроб. химиотер. 2014; 16 (4): 294–311.

[39] Park Y.S., Yoo S., Seo M.R. et al. Risk factors and clinical features of infections caused by plasmid-media­ted AmpC beta-lactamase-producing Enterobacteriaceae. Int. J. Antimicrob. 2009; 34: 38–43. DOI: 10.1016/j.ijantimicag.2009.01.009.

[40] Tacconelli E., De Angelis G., Cataldo M.A. et al. Does antibiotic exposure increase the risk of methicillinresistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J. Antimicrob. Chemo­ther. 2008; 61: 26–38. DOI: 10.1093/jac/dkm416.

RIGHTS & PERMISSIONS

Aleksandrova E.G., Abakumova T.R., Evstigneev S.V., Titarenko A.F., Khaziakhmetova V.N., Ziganshina L.E.